American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (988)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1257)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (64)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5174)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5555)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and efficacy of splenic irradiation for non-Hodgkin lymphoma
    Meeting Abstract

    Hubbeling, H.; Imber, B. S.; Wijetunga, N. A.; Tringale, K. R.; Hajj, C.; Yahalom, J.
    Blood (2022)

    Fulltext@MSK | Save
  • A risk model for CML patients with COVID-19: Importance of molecular response in the context of age, comorbidities and country income
    Meeting Abstract

    Radich, J. P.; Kok, C. H.; Chelysheva, E. Y.; Cortes, J. E.; Jiang, Q.; Mauro, M.; Milojkovic, D.; Moiraghi, B.; Nicolini, F. E.; Ongondi, M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Characterization of a large cohort of patients with nodal marginal zone lymphoma shows prolonged survival, time-to-treatment, and time-to-transformation
    Meeting Abstract

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Tub-010, a novel antibody-drug-conjugate with reduced nonspecific toxicity profile based on tub-tag technology widens the therapeutic window for the treatment of CD30+malignancies
    Meeting Abstract

    Gerlach, M.; Schmitt, S.; Cyprys, P.; Kasper, M. A.; Mai, I.; Vermeer, M. H.; Horwitz, S. M.; Fingerle-Rowson, G. R.; Vogl, A.; Schumacher, D.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for early stage classic Hodgkin lymphoma: Interim efficacy and safety results from the single-arm phase 2 study (SGN35-027 Part C)
    Meeting Abstract

    Lee, H. J.; Abramson, J. S.; Bartlett, N. L.; Burke, J. M.; Lynch, R. C.; Eva, D. D.; Hess, B. T.; Schuster, S. R.; Linhares, Y.; Ramchandren, R.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma from the phase 2 primo trial expansion phase: Impact of prior treatment and expanded safety analysis
    Meeting Abstract

    Jacobsen, E. D.; Zinzani, P. L.; Zain, J.; Mead, M.; Casulo, C.; Gritti, G.; Pinter-Brown, L. C.; Izutsu, K.; Daugherty, M.; Brammer, J. E.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Phase 3 trial of subcutaneous epcoritamab in combination with rituximab and lenalidomide (R(2)) vs R(2) among patients with relapsed or refractory follicular lymphoma (EPCORE FL-1)
    Meeting Abstract

    Falchi, L.; Morschhauser, F.; Gribben, J. G.; Huang, H.; Dinh, M.; Conlon, R.; Chen, X.; Elliot, B.; Seymour, J. F.
    Blood (2022)

    Fulltext@MSK | Save
  • Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed / refractory mantle cell lymphoma: Additional patients and extended follow-up from the phase 1/2 BRUIN study
    Meeting Abstract

    Wang, M. L.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Cheah, C. Y.; Ujjani, C. S.; Koh, Y.; Izutsu, K.; Gerson, J. N.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save